American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Plasmodium Falciparum: A Pathogenesis and Therapeutic Challenges in Combating Fatal Malaria: A Subject Review

Sunbul Jalal Shakour
Collage of Nursing, University of Kirkuk, Iraq

Received: 2025, 15, Nov
Accepted: 2025, 21, Dec
Published: 2026, 05, Jan

Annotation: Plasmodium falciparum is the most lethal malaria parasite worldwide with characteristic mature gametocytes of the crescentic form and intricate capacity by sequestration in the microvasculature of host. Its life cycle is a complex change between the Anopheles mosquito and human host with a silent hepatic phase followed by an erythrocytic pathogenic one that occurs every 48 hours. Avoidance of the host's immune response is effected by the rapid shift of expression from one PfEMP1 variant to another through antigenic variation on the surface of infected erythrocytes, mediated by 'patching' and 'segmental gene conversion'. Although Iraq has achieved an elimination status with no autochthonous transmission, the risk of re-importation and resurgence are high because of imported cases from neighboring endemic countries (Iran) and it is also under threat of vector expansion as a result of climatic changes. New management has shifted to rapid diagnostic tests and the Artemisinin-based Combination Therapies (ACTs) As well as the elimination by 2030, it faces biological and ecological issues.

Keywords: P. falciparum, Pathogenesis, Malaria Elimination, Antigenic Variation.

1. Introduction

Malaria continues to be a leading infectious disease challenge in human history with hundreds of millions of clinical cases occurring each year [1]. Of the five Plasmodium species that infect humans, P. falciparum is by far the most virulent and common type, accounting for most cases of malaria hospitalization and mortality worldwide [2, 3]. The protozoan parasite has a complex multi-stage life cycle, which includes a female Anopheles mosquito vector and a human host [4].

P. falciparum has a special clinical importance due to its unusual pathogenic features, such as infection modifying the surface of red blood cells that they occupy. This results in cytoadherence and obstruction of microvascular blood flow which may manifest in severe fatal complications like cerebral malaria, severe malarial anemia and multi-organ failure [5, 7].

At regional level, the epidemiology is different. Though sub-Saharan Africa still bears the greatest load, countries in the Eastern Mediterranean Region, as Iraq are achieving huge gains toward elimination [15]. Traditionally, Iraq has been a malaria endemic area and has managed to eliminate indigenous transmission through sustained public health interventions with zero indigenous cases reported over the last few years [13, 14]. However, the constant presence of mosquito vectors and flowing in of imported cases from endemic regions warrant continual monitoring and great caution [16].

However, even with these triumphs, the battle against P. falciparum at a global perspective is under attack by two significant biological challenges: (i) mosquito resistance to insecticides and (ii) parasite strains resistant to Artemisinin-based Combination Therapies (ACTs)[10, 11]. The present review therefore attempts to consolidate the present state of knowledge of P. falciparum biology, its pathogenic mechanisms, and the skyrocketing expansion of diagnostic and therapeutic approaches against this global menace.

2. Classification and Morphology

2.1. Taxonomic Classification

Plasmodium falciparum is a unicellular protozoa of the phylum Apicomplexa. It is distinguished by the apical complex, a group of organelles for host cell invasion [3, 9].

Kingdom: Protista

Phylum: Apicomplexa

Class: Aconoidasida

Order: Haemosporida

Family: Plasmodiidae

Genus: Plasmodium

Species: P. falciparum

2.2. Morphological Characteristics

The morphology of P. falciparum shows marked differences according to their development stage in human blood, which is essential for laboratory diagnosis of thick and thin blood smears [4, 5]:

Ring (Early Trophozoite) Stage: This is the most frequently seen stage in peripheral blood. It presents as a subtle blue, cytoplasmic rim surrounding a small red chromatin dot. A double chromatin dots or multiple infection of a single red blood cell (RBC) are characteristic of P. falciparum [3,5].

Gametocytes: In contrast to the other species of Plasmodium, the mature gametocytes of P.

falciparum have a distinctive crescent or banana shape. This characteristic morphology is an important criterion seen in the microscope. Schizonts: Mature schizonts are seldom observed in peripheral blood as they tend to get sequestered in the inner organs capillaries. Normally they are composed of 16 to 24 merozoites [3,7].



Figure (1): Plasmodium spp. morphology and genome architecture [17].

2.3. Host Cell Modification

P. falciparum causes structural rearrangement of host RBCs upon invasion. The prominent alteration is the knobs that appear as electron-dense protrusions in RBC surface. These knobs act as sites for binding of parasite proteins (such as PfEMP1) that mediate cytoadherence to the vascular endothelium [7,8].

3. Life Cycle Dynamics

The life cycle of P.falciparum is an extraordinary exercise in biological adaptation, because it involves the ability of parasites to move between a cold-blooded insect vector and a warm-blooded mammalian host. This intricate process is governed by stage-specific gene expression that permits survival of the parasite within different physiological environments [18], figure (2).

3.1. Pre-Erythrocytic Phase: The Silent Hepatic Assault

Infection begins as an infected female Anopheles mosquito introduces approximately 10-100 sporozoites into the dermis of the host during a blood meal [19]. Homing and Invasion: Sporozoites are not held in the skin; instead they enter the bloodstream during gliding motility to reach the liver within minutes. They primarily infect hepatocytes, through interaction with host heparan sulfate proteoglycans, using their Circumsporozoite Protein (CSP) [20].

Intrahepatic Schizogony: Inside a hepatocyte, the parasite will asexually replicate to enormous numbers. One sporozoite can produce between 30,000 and 40,000 merozoites in this mode over a period of 5-16 days. This phase is asymptomatic from a clinical point of view, as the parasite remains effectively concealed from the systemic immune system [21].



Figure 2: Schematic illustration of the life cycle of P. falciparum, showing the transition between the Anopheles mosquito and the human host (Liver and Blood stages) [22].

3.2. The Erythrocytic Cycle: Pathogenic Multiplication

The symptomatic phase (SP) of malaria starts when merozoites are shed from the liver to enter the blood circulation, pass into RBCs [23]. Molecular Invasion: Merozoites secrete ligands using sub-cellular organelles (micronemes and rhoptries) which establish a tight junction with the RBC membrane, through which the parasite is able to be forced into a protective vacuole in the RBC [24].

Developmental Process: Inside the RBC, the parasite develops through three recognizable morphological states referred to as Ring (early form), the metabolically active Trophozoite (which digests host hemoglobin) and the Schizont [23, 25].

Synchronized Lysis: Schizont will burst every 48 hours and release 16–24 new merozoite along with metabolic excretory wastes such as hemozoin. This coordinated disruption causes the host's inflammatory cytokines (TNF-α) and then abnormal paroxysmal fevers and chills, which are symptoms of malaria [26].

3.3. The Sporogonic Cycle: Commitment to Sex and the Vector Transmission

In order to preserve the propagation of the species, a fraction of the asexual parasites differentiate into Gametocytes by "sexual commitment" [27].

- Developing Gametocytes: In P. falciparum, gametocyte formation differs from other species and five distinct stages may take 10–12 days to develop to maturity. The mature last-stage V gametocytes are crescent or banana-shaped forms that can infect the mosquito vector [27,28].
- Fertilisation in the Vector: Following ingestion by a mosquito, temperature reduction and xanthurenic acid initiate release of male and female gametes. The zygote develops into a motile ookinete after fertilization. The ookinete invades the wall of the mosquito midgut to become an oocyst that eventually ruptures and releases respiratory sporozoites, perpetuating the cycle [21, 29].

4. Epidemiology and Global Distribution

4.1. Global Situation

Worldwide, Plasmodium falciparum is currently the predominant cause of malaria morbidity and mortality with WHO African Region bearing about 95% burden [1]. In 2022, there were approximately 249 million malaria cases globally, with P. falciparum being the predominant species in almost all endemic regions [1, 2]. The scaling up of insecticide-treated nets and artemisinin-based combination therapies has reduced transmission in many areas, but the biological threats that include drug resistance and climate change remain challenges to global progress towards eradication [2, 11].

4.2. Pan-Arab and East Mediterranean

Epidemiology of Malaria in the Arab world There is a marked heterogeneity in the pattern of malaria across the Arab countries, between malaria-free countries (Egypt and UAE) to countries with high endemicity such as Sudan, Somalia, Yemen [15]. This is because, in the Eastern Mediterranean Region, P. falciparum and P. vivax overlap, with P. falciparum being responsible for the most severe cases of malaria and most deaths in the southern tier of the region [1, 15]. Political instability and displacement of populations in some Arab countries have interfered with the implementation of control programmes, leading to local outbreaks in regions where transmission had formerly been controlled [15].

4.3. The Situation in Iraq

Iraq is a success story in the region against malaria, moving from an endemic country to e1limination phase [14]. At present, Iraq has zero indigenous cases of P. falciparum (no local transmission within its territory) [13, 14]. Nevertheless, the country is still threatened by Imported Malaria type of malaria through traveling personnel returning to Sudans from disease endemic countries such as Pakistan and India [14]. Efficient mosquito vectors, including Anopheles stephensi are reportedly abundant in different governorates of Iraq, and close surveillance is required along its borders to stop the re-introduction of the disease [16].

5. Molecular Pathogenesis and Immune Evasion

P. falciparum's extreme virulence is in large part, believed to be due to the parasite's capacity that emanates in remodeling the host RBCs profoundly. This type of remodeling enables the parasite to evade immune surveillance by the host and induces mechanical vessel occlusion [5, 18].

5.1. PfEMP1 and Cytoadherence

The most important virulence factor is the P. falciparum erythrocyte membrane protein 1 (PfEMP1). This protein is produced by the parasite and exported to the surface of the infected RBC [3, 8].

- Sequestration: PfEMP1 attaches infected RBCs to the walls of blood vessels (cytoadherence), keeping them from being processed out in the spleen where they would otherwise be cleared [7,22].
- Receptor Specificity: Distinct PfEMP1 types adher to different host receptors. Binding to EPCR (Endothelial Protein C Receptor) and ICAM-1 in the brain is prominently linked with cerebral malaria [29, 30].

5.2. Knob Formation and Membrane Stiffness

Infected RBCs acquire electron-dense protrusions called knobs at their surface [8, 22].

- Structural Role: These knobs are discrete sites for the attachment of PfEMP1 molecules that facilitate the adhesion between the cell and blood vessel wall [22].

- Decreased Deformability: The parasite digests host hemoglobin and alters the RBC cytoskeleton architecture, causing the cell to become rigid and less able to deform as it traverses through smaller capillaries [22, 24].

5.3. Rosetting and Microvascular Obstruction

P. falciparum also elicits "Rosetting," that is, an I-RBC binds several UI-RBCs [22]. Clinical Relevance: The presence of these cell clusters, combined with cytoadherence results in obstructive microvasculature leading to focal tissue hypoxia and metabolic acidosis characteristic for severe malaria [5, 31].

5.4. Antigenic Variation and Immune Escape

The parasite does this with a complex genetic "switch." The var Gene Family: Approximately ~60 "var" genes are encoded in each parasite genome, which code for distinct forms of PfEMP1 [20, 25].

Strategy for switching: No more than one var gene is expressed at once. Upon acquisition of antibodies against the dominant PfEMP1, a fraction of parasites shifts expression to another var gene so that the immune response can no longer clear this parasite and consequently an infection persists [20, 32].

6. Diagnostic and Therapeutic Strategies

Management of P. falciparum The treatment of cases of P. falciparum malaria must be prompt andcarried out on the basis on good diagnosis which means throughclinical history taking for symptoms and physical findings, as well asthrough laboratory tests that can confirm the cause of the fever.The challenge is realizing rapid an accurate diagnosis followby immediate effective antimalarial therapy to avoid a progress to severe formsof disease and death [2, 4].

6.1. Gold Standards and Rapid Diagnostic Tests

Laboratory diagnosis forms the basis of malaria control, as in elimination settings including Iraq [14].

Microscopic examination: The gold standard is microscopic examination of Giemsa-stained thick and thin blood films. Thick smears are employed for detection of the parasite (high sensitivity) and thin smears for species identification and determination of parasitemia [4, 5].

Rapid Diagnostic Tests(RDTs): These are immunochromatographic tests which identify specific parasite antigens, mainly Histidine-Rich Protein 2 (HRP2) targeted for P. falciparum. RDTs are crucial in the field secondary to a lack of microscopy [1, 33].

Molecular Methods Polymerase Chain Reaction (PCR) is a highly sensitive technique that is able to detect sub microscopic infections, and as such, it will be of crucial importance for surveillance and verification in elimination programmes [11,34].

6.2. Therapeutic Interventions

The appearance of drug resistant isolates has dramatically influenced the more recent treatment recommendations [11].

- Artemisinin-based Combination Therapy (ACT): An ACT is the recommended treatment for uncomplicated P. falciparum malaria in all endemic areas of the world. These are combinations of a rapidly acting artemisinin derivative and a slow-acting partner drug (e.g., Artemether Lumefantrine) to ensure full parasite clearance and minimize the risk of resistance [1, 2].
- Severe Malaria Treatment: The treatment of choice for severe cases is Intravenous Artesunate which has been shown to decrease mortality compared to older treatments, such as Quinine [4, 35].

- Vaccines and Chemoprevention: Prompting the recent suggestion of the RTS,S/AS01 and R21/Matrix-M vaccines are two big steps for prevention, with a historical impact particularly on children living in high transmission areas [1].

6.3. Challenges in Diagnosis and Treatment

- HRP2 Deletions: A subset of P. falciparum parasites have been shown to delete the pfhrp2/3 genes causing false negative results on a conventional RDT, complicting case management [1, 36].
- Drug Resistance: The emerging resistance to artemisinin in South East Asia and now increasingly also in parts of Africa, is a significant threat to global malaria control [11, 35].

7. Future Challenges and Control Prospects

Premature elimination of malaria by 2030 challenges itself with unprecedented biological and ecological complexities that can only be addressed via cutting-edge genomic and environmental interventions [1, 2].

7.1. Biological Resistance: The Double Threat

The development of resistance in the parasite and its vector is presently one of the most pressing threats to P. falciparum control[11].

- Resistance to Antimalarials: The spread of Kelch13 mutations causing artemisinin partial resistance has now been identified in Africa rendering first-line ACTs ineffective [11, 37].
- Resistance to insecticides: Anopheles are also becoming more resistant at the physiological level, especially against pyrethroids and carbamates--the leading chemicals used in ITNs [16, 38].

7.2. Climate Change and Vector Expansion

As different geographical areas are becoming less or more suitable for malaria transmission, the environmental changes contribute to redefining the malaria map: this may re-introduce the disease in countries that are already in the elimination phase (e.g., Iraq) [14].

- Temperature changes: Global warming reduces the extrinsic incubation period of the parasite in mosquitoes, so resulting in rapid transmission cycles [39].
- Urban malaria: Anopheles stephensi invasion of emerging urban areas in the Middle East and Africa signifies a new threat, because this vector is able to propagate in artificial man-made water bodies as opposed to classical rural vectors [40].

7.3. Innovative Control Strategies

In response to such challenges, the scientific community now focuses on “next generation” control tools [18].

- Gene Drive Technology: Candidate use of CRISPR-Cas9 for population replacement, “driving” infertility genes through wild mosquito populations or making them incapable of transmitting P. falciparum [41].
- Monoclonal Antibodies: The recent discovery of extremely long active monoclonal antibodies provides extreme degree of seasonal shielding similar to a “passive vaccine” of high risk groups [42].
- AI and Genomic Surveillance: AI applied to forecasting outbreaks and real time genomic sequencing to follow the spread of drug-resistant strains [43,44].

8. Conclusions

P. falciparum is still the deadliest malaria parasite because of its singular capacity to microvascular sequester and to rapidly escape its immune landscape, thus causing severe clinical

syndromes. Iraq may be looked at by other countries in the region as a model for indigenous case elimination, albeit imported malaria and competent vectors call for vigilance. The global challenges of drug resistance and diagnostic obfuscation are ultimately defeated only if we move towards seamless genomic surveillance of the parasite, and make a systematic push for next-generation vaccines in order to eliminate the disease once and for all.

References

1. World Health Organization. World malaria report 2023. Geneva: World Health Organization; 2023.
2. Ashley EA, Pyae Phyo A, Woodrow CJ. Malaria. Lancet. 2018 Apr 21;391(10130):1608-1621.
3. Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and Disease. Cell. 2016 Oct 20;167(3):610-624.
4. White NJ. Malaria. In: Manson's Tropical Infectious Diseases. 24th ed. Philadelphia: Elsevier; 2023. p. 532-600.
5. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. Nature. 2002 Feb 7;415(6872):673-9.
6. Wahlgren M, Goel S, Akhouri RR. Variant surface antigens of Plasmodium falciparum and their roles in severe malaria. Nat Rev Microbiol. 2017 Aug;15(8):479-491.
7. Deitsch KW, Hviid L. Establishing a model for the pathogenesis of severe Plasmodium falciparum malaria. Trends Parasitol. 2021;37(12):1043-1052.
8. Haeggström M, Deitsch K, Hviid L, Jensen AT, Miller LH. The Role of PfEMP1 in Cytoadherence and Sequestration. Frontiers in Cellular and Infection Microbiology. 2020;10:145.
9. Phillips MA, Burrows JN, Manyando C, et al. Malaria. Nature Reviews Disease Primers. 2017;3:17050.
10. Menard D, Ariey F. Plasmodium falciparum resistance to artemisinin: Current status and future challenges. Med Sci (Paris). 2015;31(11):980-6.
11. Haldar K, Bhattacharjee S, Safeukui I. Drug resistance in Plasmodium falciparum malaria. Nat Rev Microbiol. 2018;16(3):156-170.
12. White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084-1092.
13. Ministry of Health, Iraq. National Malaria Elimination Program: Annual Epidemiological Report. Baghdad: MOH Press; 2022.
14. Rasheed HI, Hasan HF, Ahmed NA. Molecular Characterization of Human Cryptosporidium Isolates from in Kirkuk, Iraq. Iraqi Journal of Science. 2025 Apr;66(4):1516–1524.
15. WHO Regional Office for the Eastern Mediterranean. Malaria elimination in the Eastern Mediterranean Region: Progress and challenges. Cairo: WHO-EMRO; 2021.
16. Hama AA, Al-Zubaidi F, Al-Azawi A. Distribution and bionomics of Anopheles mosquitoes in Iraq. International Journal of Entomology Research. 2018;3(2):124-129.
17. Bourgard C, Albrecht L, Kayano ACAV, Sunnerhagen P. Plasmodium vivax biology: insights provided by genomics, transcriptomics and proteomics. Front Cell Infect Microbiol. 2018;8:34.
18. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. That was then but this is now: malaria research in the post-genomic era. Science. 2010;328(5980):862-6.

19. Frischknecht F, Mueller AK. The Cell Biology of Malaria Invasion: Gametes to Sporozoites. Cold Spring Harb Perspect Med. 2017;7(2):a025510.

20. Pradel G. Proteins of the malaria parasite sexual stages: expression, function and immunity. Cell Microbiol. 2007;9(9):2113-24.

21. Bennink S, Kiesow MJ, Pradel G. The development of malaria parasites in the mammalian host. Int J Med Microbiol. 2016;306(5):300-11.

22. Enomoto M, Kawazu S-I, Kawai S, Furuyama W. Blockage of spontaneous Ca^{2+} oscillation causes cell death in intraerythrocytic Plasmodium falciparum. PLoS One. 2012;7(7):e39499.

23. Tilley L, Dixon MW, Kirk K. The Plasmodium falciparum-infected red blood cell: Structural and functional changes. Int J Parasitol. 2011;41(1):5-22.

24. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell. 2006;124(4):755-66.

25. Goldberg DE. Hemoglobin degradation. Curr Top Microbiol Immunol. 2005;295:275-91.

26. Gravenor MB, Kwiatkowski D. Analysis of the 48-hour cycle of Plasmodium falciparum in vivo. Parasitology. 1998;117 (Pt 4):311-6.

27. Josling GA, Llinás M. Sexual commitment in Plasmodium falciparum: a molecular pivot. Trends Parasitol. 2015;31(12):603-10.

28. Dixon MW, et al. Shape-shifting gametocytes: how and why does P. falciparum go banana-shaped? Trends Parasitol. 2012;28(11):471-8.

29. Aly AS, Vaughan AM, Kappe SH. Malaria parasite development in the mosquito and infection of the mammalian host. Annu Rev Microbiol. 2009;63:195-221.

30. Turner L, Lavstsen T, Berger SS, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5.

31. Avril M, Bernabeu M, Benjamin M, et al. Interaction between endothelial protein C receptor and intercellular adhesion molecule 1 mediates P. falciparum cytoadherence. Science. 2012;338(6112):1230-3.

32. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of Plasmodium falciparum-infected red blood cells to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol Med. 2009;11:e16.

33. Guizot-Noël A, et al. The var genes of Plasmodium falciparum: a central role in virulence and immune evasion. Trends Parasitol. 2021;37(12):1043-52.

34. Moody A. Rapid diagnostic tests for malaria. Clin Microbiol Rev. 2002;15(1):66-78.

35. Okell LC, et al. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nature Communications. 2012;3(1):1237.

36. Dondorp AM, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. The Lancet. 2005;366(9490):717-25.

37. Cheng Q, et al. Plasmodium falciparum parasites lacking histidine-rich protein 2 and 3: a review and recommendations for surveillance. BMJ Global Health. 2020;5(11):e003357.

38. Uwimana A, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum in Rwanda. Nature Medicine. 2020;26(10):1602-1608.

39. Hancock PA, et al. The evolution of insecticide resistance in Anopheles mosquitoes. Science. 2020;368(6492):748-751.

40. Ryan SJ, et al. Global expansion of human malaria transmission risk under climate change. Nature Communications. 2023;14(1):1-12.
41. Sinka ME, et al. Anopheles stephensi in Africa: a silent threat to its urban populations. BMJ Global Health. 2020;5(10):e003279.
42. Kyrou K, et al. A site-specific gene drive system across the entire population of Anopheles gambiae. Nature Biotechnology. 2018;36(11):1062-1066.
43. Saleh AH, Abbood HAR. The role of silver (Ag) nanoparticles synthesis by Penicillium spp against the toxicity of Echinococcus granulosus in adult albino male rats. Medico Legal Update. 2020;20(1):532–537.
44. Dalmat R, et al. Artificial intelligence for malaria elimination: a review. Malaria Journal. 2019;18(1):165.
45. Jacobson JO, et al. Genomic surveillance for malaria elimination. Trends in Parasitology. 2021;37(10):855-866.